Monday, June 15, 2026

Report: North Korea Grooms Kim’s Daughter for Succession, Dismisses Rumors of Son

NIS reports Kim Ju-ae's low-profile China visit strengthens her potential successor narrative, while Kim's health and diplomatic strategies are analyzed.

2026: A New Chapter in China-North Korea Relations – What You Need to Know

North Korea welcomes President Xi Jinping's visit, emphasizing the strengthening of North Korea-China friendly relations.

Hyundai’s INSTEROID: A Playful Twist on Futuristic Design and Innovation

Hyundai unveils the INSTEROID, an innovative concept car aimed at enhancing the INSTER's design for global markets with immersive experiences.

Tag: immunotherapy

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

Revolutionary Discovery: How Environmental Stress Affects Cold Tumors and NK Cell Function

A study reveals cold tumors' causes extend beyond genetics to include environmental stress and lifestyle, impacting immune response.

Daewoong Pharmaceutical Expands Biosimilar Push With Dupixent Copy Deal and Global CDMO Partnership

Daewoong Pharmaceutical partners with Chime Biologics to develop a Dupixent biosimilar, enhancing its global biosimilar business expansion.

Lunit to Present Five AI Biomarker Studies at ASCO 2026 Highlighting Expanded Clinical Applications

Lunit will present five AI studies at ASCO 2026, showcasing biomarker analysis for cancer treatment and patient response prediction.

How Dong-A ST’s SC5024 and ADC Innovations Could Change the Game Cancer Pipeline

Dong-A ST showcased its innovative cancer pipeline at AACR 2026, featuring promising preclinical findings and advanced therapeutic strategies.

Lunit’s AI-based bile duct cancer study selected for rapid oral presentation at U.S. oncology conference

Lunit will present five research abstracts at ASCO 2026, showcasing the expanding role of AI biomarkers in cancer treatment.

AACR 2026: How Korean Biotech Firms Are Leading the Charge in Cancer Research

AACR 2026 in San Diego will showcase South Korea's cancer tech innovations, featuring firms like Hanmi and Samsung Biologics.

Revolutionary Immune Therapy for Colon Cancer: How MAFB Protein Manipulation Enhances Treatment Response

Korea University researchers have developed a new colorectal cancer treatment strategy by regulating tumor-associated macrophages to enhance immune response.

How Hanmi’s Dual Inhibitor HM97662 is Revolutionizing Cancer Treatment: Key Insights from AACR 2026

Hanmi Pharmaceutical to present nine groundbreaking cancer research studies at AACR 2026, showcasing innovative therapies and AI-driven analytics.

Unlocking the Future of Cancer Treatment: UCI-101 CAR-NK Therapy by UCI Therapeutics

Matica BioLabs partners with UC Therapeutics to manufacture CAR-NK cell therapy, enhancing cancer treatment through dual-targeting technology.

GC Cell’s CAR-NK: Revolutionizing Solid Tumor Treatment with New Patent

GC Cell has patented an immunotherapy targeting solid tumors using its CAR-NK platform, aiming for safer, cost-effective treatments.

How Keytruda is Revolutionizing Cancer Treatment: Expanded Coverage for Stomach Cancer in 2026

Keytruda's insurance coverage expands to stomach cancer, solidifying its status as a leading universal immunotherapy for various cancers.

GCC2005: The Breakthrough CAR-NK Therapy for T-Cell Lymphoma Unveiled at TCLF 2026

GC Cell presents promising CD5-targeting CAR-NK therapy GCC2005 for T-cell lymphoma, showing significant efficacy and safety at TCLF.

Revolutionary Cancer Treatment SJ-650: What Makes It a Game Changer in Oncology?

SillaJen's SJ-650 cancer treatment platform gains recognition with publication in Molecular Therapy, showcasing its innovative approach and efficacy.

Revolutionary mRNA Cancer Treatment Shows 49% Survival Improvement: What You Need to Know

A study shows mRNA-based cancer treatments significantly improve survival rates, marking a breakthrough in precision therapy for melanoma.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.